PHAR vs. JANX, DCPH, AMRX, VERA, RCKT, PTGX, MRVI, ZLAB, AMPH, and CPRX
Should you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Janux Therapeutics (JANX), Deciphera Pharmaceuticals (DCPH), Amneal Pharmaceuticals (AMRX), Vera Therapeutics (VERA), Rocket Pharmaceuticals (RCKT), Protagonist Therapeutics (PTGX), Maravai LifeSciences (MRVI), Zai Lab (ZLAB), Amphastar Pharmaceuticals (AMPH), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical preparations" industry.
Janux Therapeutics (NASDAQ:JANX) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations.
Janux Therapeutics currently has a consensus target price of $66.29, indicating a potential upside of 57.82%. Pharming Group has a consensus target price of $37.00, indicating a potential upside of 330.23%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pharming Group is more favorable than Janux Therapeutics.
Pharming Group has a net margin of -4.01% compared to Pharming Group's net margin of -762.92%. Janux Therapeutics' return on equity of -4.61% beat Pharming Group's return on equity.
Janux Therapeutics received 11 more outperform votes than Pharming Group when rated by MarketBeat users. Likewise, 60.53% of users gave Janux Therapeutics an outperform vote while only 52.17% of users gave Pharming Group an outperform vote.
In the previous week, Pharming Group had 6 more articles in the media than Janux Therapeutics. MarketBeat recorded 7 mentions for Pharming Group and 1 mentions for Janux Therapeutics. Pharming Group's average media sentiment score of 1.89 beat Janux Therapeutics' score of 0.59 indicating that Janux Therapeutics is being referred to more favorably in the media.
Pharming Group has higher revenue and earnings than Janux Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.
75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 35.4% of Janux Therapeutics shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Janux Therapeutics has a beta of 3.72, suggesting that its stock price is 272% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500.
Summary
Janux Therapeutics and Pharming Group tied by winning 9 of the 18 factors compared between the two stocks.
Get Pharming Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pharming Group Competitors List
Related Companies and Tools
